Shancheng Ren

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2014960/publications.pdf

Version: 2024-02-01

63 papers	4,731 citations	159585 30 h-index	110387 64 g-index
67 all docs	67 docs citations	67 times ranked	7886 citing authors

#	Article	IF	Citations
1	Cyclin Dâ€“CDK4 kinase destabilizes PD-L1 via cullin 3â€“SPOP to control cancer immune surveillance. Nature, 2018, 553, 91-95.	27.8	660
2	RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Research, 2012, 22, 806-821.	12.0	352
3	Long Noncoding RNA MALAT-1 is a New Potential Therapeutic Target for Castration Resistant Prostate Cancer. Journal of Urology, 2013, 190, 2278-2287.	0.4	292
4	Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. European Journal of Cancer, 2013, 49, 2949-2959.	2.8	287
5	Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKTâ€“mTORC1 activation. Nature Medicine, 2017, 23, 1055-1062.	30.7	225
6	Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. Nature Cell Biology, 2021, 23, 87-98.	10.3	209
7	A genomic and epigenomic atlas of prostate cancer in Asian populations. Nature, 2020, 580, 93-99.	27.8	183
8	The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1117-1123.	1.6	174
9	Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer. Oncotarget, 2014, 5, 11091-11102.	1.8	160
10	Integration of Metabolomics and Transcriptomics Reveals Major Metabolic Pathways and Potential Biomarker Involved in Prostate Cancer. Molecular and Cellular Proteomics, 2016, 15, 154-163.	3.8	149
11	Prostate cancer in Asia: A collaborative report. Asian Journal of Urology, 2014, 1, 15-29.	1.2	136
12	Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression. European Urology, 2018, 73, 322-339.	1.9	130
13	Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation. Molecular Cell, 2015, 59, 904-916.	9.7	129
14	Microvesicles and chemokines in tumor microenvironment: mediators of intercellular communications in tumor progression. Molecular Cancer, 2019, 18, 50.	19.2	108
15	Integration of lipidomics and transcriptomics unravels aberrant lipid metabolism and defines cholesteryl oleate as potential biomarker of prostate cancer. Scientific Reports, 2016, 6, 20984.	3.3	103
16	Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer. Cell Reports, 2016, 15, 599-610.	6.4	101
17	Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly. Molecular Cancer, 2019, 18, 170.	19.2	79
18	Metagenomic and metatranscriptomic analysis of human prostate microbiota from patients with prostate cancer. BMC Genomics, 2019, 20, 146.	2.8	73

#	Article	IF	Citations
19	A feed-forward regulatory loop between androgen receptor and PlncRNA-1 promotes prostate cancer progression. Cancer Letters, 2016, 374, 62-74.	7.2	64
20	Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. European Urology, 2018, 73, 524-532.	1.9	60
21	Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer. EMBO Molecular Medicine, 2021, 13, e12798.	6.9	59
22	Metabolomics and transcriptomics profiles reveal the dysregulation of the tricarboxylic acid cycle and related mechanisms in prostate cancer. International Journal of Cancer, 2018, 143, 396-407.	5.1	57
23	SPOP E3ÂUbiquitin Ligase Adaptor Promotes Cellular Senescence by Degrading the SENP7 deSUMOylase. Cell Reports, 2015, 13, 1183-1193.	6.4	55
24	Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer. PLoS Genetics, 2017, 13, e1006748.	3.5	54
25	SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression. Developmental Cell, 2019, 48, 329-344.e5.	7.0	53
26	Large-scale association analysis in Asians identifies new susceptibility loci for prostate cancer. Nature Communications, 2015, 6, 8469.	12.8	51
27	Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer. Journal of Molecular Medicine, 2012, 90, 1121-1132.	3.9	45
28	Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduction and Targeted Therapy, 2022, 7, .	17.1	40
29	Histone H4 Lys 20 methyltransferase SET8 promotes androgen receptor-mediated transcription activation in prostate cancer. Biochemical and Biophysical Research Communications, 2014, 450, 692-696.	2.1	34
30	Development and external multicenter validation of Chinese Prostate Cancer Consortium prostate cancer risk calculator for initial prostate biopsy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 416.e1-416.e7.	1.6	33
31	Upregulation of Scavenger Receptor B1 Is Required for Steroidogenic and Nonsteroidogenic Cholesterol Metabolism in Prostate Cancer. Cancer Research, 2019, 79, 3320-3331.	0.9	33
32	Novel Long Non-coding RNA lncAMPC Promotes Metastasis and Immunosuppression in Prostate Cancer by Stimulating LIF/LIFR Expression. Molecular Therapy, 2020, 28, 2473-2487.	8.2	33
33	CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer. Nature Communications, 2021, 12, 1781.	12.8	32
34	Multiple Expression Assessments of ACE2 and TMPRSS2 SARS-CoV-2 Entry Molecules in the Urinary Tract and Their Associations with Clinical Manifestations of COVID-19 . Infection and Drug Resistance, 2020, Volume 13, 3977-3990.	2.7	31
35	Plateau effect of prostate cancer riskâ€associated SNPs in discriminating prostate biopsy outcomes. Prostate, 2013, 73, 1824-1835.	2.3	29
36	RED-ML: a novel, effective RNA editing detection method based on machine learning. GigaScience, 2017, 6, 1-8.	6.4	29

#	Article	IF	Citations
37	Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer. Oncogene, 2019, 38, 4875-4884.	5.9	27
38	The previously uncharacterized lncRNA APP promotes prostate cancer progression by acting as a competing endogenous RNA. International Journal of Cancer, 2020, 146, 475-486.	5.1	27
39	LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression. Cell Death and Disease, 2020, 11, 638.	6.3	26
40	Clinical utility of a novel urine-based gene fusion TTTY15-USP9Y in predicting prostate biopsy outcome. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 384.e9-384.e20.	1.6	25
41	Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy. Clinical Cancer Research, 2022, 28, 552-567.	7.0	25
42	Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer. European Journal of Cancer, 2020, 134, 29-40.	2.8	22
43	An acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors. Cell Reports, 2021, 34, 108744.	6.4	17
44	Identification of specific DNA methylation sites on the Y-chromosome as biomarker in prostate cancer. Oncotarget, 2015, 6, 40611-40621.	1.8	17
45	SEMA3A-mediated crosstalk between prostate cancer cells and tumor-associated macrophages promotes androgen deprivation therapy resistance. Cellular and Molecular Immunology, 2021, 18, 752-754.	10.5	16
46	Extended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation. JAMA Surgery, 2022, 157, 693.	4.3	16
47	Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0â€“10.0 ng/ml. PLoS ONE, 2015, 10, e0130308.	2.5	14
48	SARS-CoV-2 effects in the genitourinary system and prospects of sex hormone therapy. Asian Journal of Urology, 2021, 8, 303-314.	1.2	13
49	Single-port transperitoneal robotic-assisted laparoscopic radical prostatectomy (spRALP): Initial experience. Asian Journal of Urology, 2019, 6, 294-297.	1.2	12
50	Robotic Perineal Radical Prostatectomy: Initial Experience with the da Vinci Si Robotic System. Urologia Internationalis, 2020, 104, 710-715.	1.3	12
51	Genome-wide association studies on prostate cancer: the end or the beginning?. Protein and Cell, 2013, 4, 677-686.	11.0	11
52	Regression of castration-resistant prostate cancer by a novel compound QW07 targeting androgen receptor N-terminal domain. Cell Biology and Toxicology, 2020, 36, 399-416.	5.3	11
53	Epigenetic Pattern on the Human Y Chromosome Is Evolutionarily Conserved. PLoS ONE, 2016, 11, e0146402.	2.5	11
54	Nomograms for predicting Gleason upgrading in a contemporary Chinese cohort receiving radical prostatectomy after extended prostate biopsy: development and internal validation. Oncotarget, 2016, 7, 17275-17285.	1.8	10

#	Article	IF	Citations
55	OTUD6A promotes prostate tumorigenesis via deubiquitinating Brg1 and AR. Communications Biology, 2022, 5, 182.	4.4	10
56	Percent free prostate-specific antigen for prostate cancer diagnosis in Chinese men with a PSA of 4.0â€“10.0Âng/mL: Results from the Chinese Prostate Cancer Consortium. Asian Journal of Urology, 2015, 2, 107-113.	1.2	6
57	Super-veil nerve-sparing extraperitoneal pure single-port robotic-assisted radical prostatectomy on da Vinci Si robotic system. World Journal of Urology, 2022, , 1.	2.2	3
58	Establishment of a Chinese bladder cancer cell line (T921) with high metastatic activity. In Vitro Cellular and Developmental Biology - Animal, 2013, 49, 668-678.	1.5	2
59	Transvesical Single-Port Robotic Radical Prostatectomy on da Vinci Si: A Safe Access for Patients with Previous Open Surgery for Rectal Cancer. Videourology (New Rochelle, N Y), 2022, 36, .	0.1	2
60	The older the better: The characteristic of localized prostate cancer in Chinese men. Asian Journal of Urology, 2015, 2, 129-132.	1.2	1
61	How can plasma RNA be used to diagnose prostate cancer?. Expert Review of Anticancer Therapy, 2017, 17, 5-7.	2.4	1
62	Assessing the safety and feasibility of neoadjuvant hormone and radiation therapy followed by robot-assisted radical prostatectomy for treating locally advanced prostate cancer: protocol for an open-label, dose-escalation, single-centre, phase I clinical trial. BMJ Open, 2020, 10, e038678.	1.9	1
63	A first-in-human phase 1 study of proxalutamide (GT0918), a dual MOA androgen receptor blocker in patients with advanced CRPC.. Journal of Clinical Oncology, 2017, 35, e16511-e16511.	1.6	0